Test Price
4,500 AED✅ Home Collection Available
Comprehensive Leukemia Panel (SNVs, Small INDELs, CNVs) in UAE | 4500 AED | DHA Licensed Facility
Executive Summary & Core Metrics
Clinical & Regulatory Assurance
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily 8 AM–11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance with DHA-Licensed Specialist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Core Metrics
- Price: AED 4,500 (inclusive of professional interpretation and digital report).
- Turnaround Time: 14–21 business days.
- Sample Type: Peripheral blood (no fasting required).
- Regulatory Oversight: DHA License 1143 – Dubai Healthcare City.
Test Overview & Methodology
This comprehensive leukemia panel uses Next-Generation Sequencing (NGS) to simultaneously detect single nucleotide variants (SNVs), small insertions/deletions (INDELs), and copy number variations (CNVs) across more than 50 leukemia-associated genes. The high-throughput parallel sequencing enables precise diagnosis, risk stratification, and therapy selection for both acute and chronic leukemias.
| Parameter | Our Comprehensive NGS Leukemia Panel | Traditional Karyotyping / FISH Panel |
|---|---|---|
| Methodology | Next-Generation Sequencing (NGS) – high-throughput parallel sequencing | Cytogenetic Karyotyping & Fluorescence In Situ Hybridization (FISH) |
| Mutation Types Detected | SNVs, small INDELs, CNVs across 50+ genes | Large chromosomal abnormalities, specific translocations |
| Turnaround Time | 14–21 days | 10–21 days (culture-dependent) |
| Sensitivity / Specificity | High (detects subclonal variants) | Moderate; limited to established aberrations |
Physician Insight & Safety Protocols
“This NGS-based leukemia panel provides highly detailed genomic information essential for modern hematology. However, results must always be interpreted alongside the full clinical picture, including bone marrow findings, blood counts, and symptoms. Genetic testing complements but does not replace expert clinical evaluation. A consultation with a hematologist-oncologist is strongly advised before making any treatment decisions.”
Important Safety Precautions
- This test is not a substitute for emergency care. If you experience uncontrolled bleeding, high fever with neutropenia, or severe fatigue with signs of organ failure, seek immediate medical attention.
- Do not discontinue or alter any prescribed medication without consulting your treating physician.
- Results are for informational and clinical guidance purposes; management decisions must be made by your healthcare provider.
Test Exclusion Criteria
- Not intended for asymptomatic individuals without a clinical suspicion of hematologic malignancy – must be ordered under specialist supervision.
- Minors (<18 years) require parental/guardian consent in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Patients with known pre-existing genetic syndromes should discuss test limitations with their genetic counselor prior to collection.
Patient FAQ & Clinical Guidance
1. What does the Comprehensive Leukemia Panel test for?
📌 Snippet: This NGS-based test sequences DNA from your peripheral blood to identify driver mutations (SNVs, INDELs, CNVs) in more than 50 genes associated with acute and chronic myeloid and lymphoid leukemias. It aids diagnosis, risk classification, and targeted therapy selection.
2. How long will it take to receive my results?
📌 Snippet: The standard turnaround time is 14–21 business days. Each sample undergoes quality control, library preparation, sequencing, and bioinformatics analysis. The final report includes an interpretation guide reviewed by a molecular pathologist.
3. Do I still need a bone marrow biopsy after this blood test?
📌 Snippet: In most clinical scenarios, bone marrow biopsy remains essential for definitive diagnosis, staging, and assessment of cellular morphology. This blood-based panel provides non-invasive genetic insight but does not replace tissue sampling when indicated by your hematologist.
UAE Regulatory & Data Privacy Adherence
Data Privacy & Compliance Framework
All genetic and personal data is processed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Your data is encrypted, stored within secure UAE-based servers, and never shared with third parties without explicit consent. DNA Labs UAE is a DHA-licensed facility (License 1143) operating under the regulatory oversight of the Dubai Health Authority.
Clinical & Logistical Metadata
| Test Name | Comprehensive Leukemia Panel (SNVs, small INDELs, CNVs) |
| Price (AED) | AED 4,500 (inclusive of professional interpretation and digital report) |
| Turnaround Time | 14–21 business days |
| Sample Type / Matrix | Peripheral blood (no fasting required) |
| Methodology Used | Next-Generation Sequencing (NGS) – high-throughput parallel sequencing for SNVs, INDELs, and CNVs across 50+ leukemia-associated genes |
| ICD-10-CM Code | C95.9 (Leukemia, unspecified) |
| LOINC Code | 91847-0 (Leukemia NGS panel) |
| DHA Facility License & Address | DHA License 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE (operated by DNA Labs UAE) |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians